Oramed Pharmaceuticals Crecimiento futuro
Future controles de criterios 0/6
Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Oramed Pharmaceuticals.
Información clave
n/a
Tasa de crecimiento de los beneficios
n/a
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Pharmaceuticals | 21.0% |
Tasa de crecimiento de los ingresos | n/a |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | Low |
Última actualización | 24 Jan 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
May 03Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Dec 22Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality
Sep 21Oramed to hand Korean rights for insulin capsule
Sep 09Oramed to report early-stage trial data for oral COVID-19 shot in 3Q
Jul 07Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?
Jun 12Oramed And Oral Insulin: Can This Small Company Really Do It?
Apr 14Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Feb 23Oramed And The Hurdles Of Developing Oral Insulin
Dec 23Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Nov 02Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress
Oct 04We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Jul 21Oramed reaches 50% enrollment in late-stage oral insulin study
Jun 08Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Apr 06The Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Is Up 110% And Shareholders Are Boasting About It
Feb 12Oramed Pharmaceuticals EPS beats by $0.42, revenue in-line
Jan 14Why Oramed Pharmaceuticals' (NASDAQ:ORMP) CEO Pay Matters
Jan 08Oramed's obesity drug candidate shows decrease in glucose levels
Dec 23We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth
Dec 04Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2024 | 1 | -11 | N/A | N/A | 2 |
12/31/2023 | 1 | 6 | -11 | -10 | N/A |
9/30/2023 | 2 | -16 | -17 | -17 | N/A |
6/30/2023 | 3 | -20 | -19 | -18 | N/A |
3/31/2023 | 3 | -30 | -25 | -24 | N/A |
12/31/2022 | 3 | -37 | -28 | -28 | N/A |
9/30/2022 | 3 | -46 | -39 | -39 | N/A |
6/30/2022 | 3 | -46 | -43 | -43 | N/A |
3/31/2022 | 3 | -40 | -39 | -39 | N/A |
12/31/2021 | 3 | -35 | -33 | -33 | N/A |
11/30/2021 | 3 | -25 | -22 | -22 | N/A |
8/31/2021 | 3 | -22 | -22 | -21 | N/A |
5/31/2021 | 3 | -18 | -18 | -17 | N/A |
2/28/2021 | 3 | -15 | -16 | -15 | N/A |
12/31/2020 | 3 | -22 | -26 | -25 | N/A |
11/30/2020 | 3 | -15 | -16 | -16 | N/A |
8/31/2020 | 3 | -12 | -13 | -12 | N/A |
5/31/2020 | 3 | -11 | -13 | -13 | N/A |
2/29/2020 | 3 | -13 | -14 | -14 | N/A |
11/30/2019 | 3 | -13 | -12 | -12 | N/A |
8/31/2019 | 3 | -14 | -13 | -13 | N/A |
5/31/2019 | 3 | -15 | -14 | -14 | N/A |
2/28/2019 | 3 | -15 | -14 | -14 | N/A |
11/30/2018 | 3 | -14 | -16 | -16 | N/A |
8/31/2018 | 2 | -13 | -15 | -15 | N/A |
5/31/2018 | 2 | -12 | -12 | -12 | N/A |
2/28/2018 | 2 | -10 | -11 | -11 | N/A |
11/30/2017 | 2 | -10 | N/A | -10 | N/A |
8/31/2017 | 2 | -10 | N/A | -6 | N/A |
5/31/2017 | 2 | -13 | N/A | 3 | N/A |
2/28/2017 | 2 | -13 | N/A | 3 | N/A |
11/30/2016 | 1 | -11 | N/A | 8 | N/A |
8/31/2016 | 1 | -11 | N/A | 5 | N/A |
5/31/2016 | 0 | -8 | N/A | -3 | N/A |
2/29/2016 | 0 | -8 | N/A | -2 | N/A |
11/30/2015 | N/A | -8 | N/A | -6 | N/A |
8/31/2015 | N/A | -7 | N/A | -5 | N/A |
5/31/2015 | N/A | -7 | N/A | -5 | N/A |
2/28/2015 | N/A | -7 | N/A | -5 | N/A |
11/30/2014 | N/A | -6 | N/A | -5 | N/A |
8/31/2014 | N/A | -6 | N/A | -4 | N/A |
5/31/2014 | N/A | -5 | N/A | -4 | N/A |
2/28/2014 | N/A | -4 | N/A | -4 | N/A |
11/30/2013 | N/A | -4 | N/A | -3 | N/A |
8/31/2013 | N/A | -4 | N/A | -3 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de ORMP es superior a la tasa de ahorro (2.3%).
Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de ORMP crezcan más deprisa que el mercado US
Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de ORMP crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de ORMP crezcan más rápido que el mercado de US.
Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de ORMP crezcan a un ritmo superior a 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la Rentabilidad de los fondos propios de ORMP se prevé elevada dentro de 3 años.